Literature DB >> 24184554

Homeostasis of human NK cells is not IL-15 dependent.

Herve Lebrec1, Michelle J Horner, Kevin S Gorski, Wayne Tsuji, Dong Xia, Wei-Jian Pan, Gary Means, Greg Pietz, Nianyu Li, Marc Retter, Kathy Shaffer, Neha Patel, Padma K Narayanan, Eric A Butz.   

Abstract

IL-15 is a proinflammatory cytokine that plays an important role in the development and activation of NK cells and is a potential target for inflammatory disease therapy. Studies conducted in IL-15- and IL-15R knockout mice identified IL-15 as an important cytokine for NK cell homeostasis. Consistent with this information derived from genetically modified mice, we demonstrated that neutralizing IL-15 with a mouse anti-mouse IL-15 mAb (M96) depletes C57BL/6 mouse NK cells. An mAb directed against macaque IL-15 (Hu714MuXHu) was manufactured and demonstrated to block IL-15-induced activation of nonhuman primate (NHP) NK cells in vitro. Neutralization of macaque IL-15 by parenteral administration of Hu714MuXHu reduces (>95%) circulating NK cell counts in NHPs. A blocking mAb directed against human IL-15 (huIL-15; AMG 714) was manufactured. Unexpectedly, when human subjects were treated with the blocking anti-IL-15 Ab AMG 714 in clinical trials, no reductions in circulating NK cell counts were observed despite achieving significantly higher exposures than the levels of Hu714MuXHu needed to cause NK cell count reductions in NHPs in vivo. Both AMG 714 and Hu714MuXHu are able to block huIL-15 activity in a human T cell blast proliferation and IFN-γ production assay. Both Abs block huIL-15-mediated Stat5 activation and CD69 expression in human NK cells. Collectively, these results demonstrate that NK cell homeostasis is obligatorily dependent upon IL-15 in both mice and NHPs, but that IL-15 is dispensable for maintenance of circulating human NK cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24184554     DOI: 10.4049/jimmunol.1301000

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.

Authors:  Maren Q DeGottardi; Afam A Okoye; Mukta Vaidya; Aarthi Talla; Audrie L Konfe; Matthew D Reyes; Joseph A Clock; Derick M Duell; Alfred W Legasse; Amit Sabnis; Byung S Park; Michael K Axthelm; Jacob D Estes; Keith A Reiman; Rafick-Pierre Sekaly; Louis J Picker
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

Review 2.  Therapeutic approaches for celiac disease.

Authors:  Nicholas M Plugis; Chaitan Khosla
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-05-09       Impact factor: 3.043

3.  IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses.

Authors:  Rosa M Santana Carrero; Figen Beceren-Braun; Sarai C Rivas; Shweta M Hegde; Achintyan Gangadharan; Devin Plote; Gabriel Pham; Scott M Anthony; Kimberly S Schluns
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-26       Impact factor: 11.205

4.  Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.

Authors:  Daniel J Neitzke; Jacob S Bowers; Kristina Andrijauskaite; Nathaniel S O'Connell; Elizabeth Garrett-Mayer; John Wrangle; Zihai Li; Chrystal M Paulos; David J Cole; Mark P Rubinstein
Journal:  Cancer Immunol Immunother       Date:  2017-03-09       Impact factor: 6.968

5.  Enzymatic synthesis of core 2 O-glycans governs the tissue-trafficking potential of memory CD8+ T cells.

Authors:  Jossef F Osborn; Jana L Mooster; Samuel J Hobbs; Michael W Munks; Conrad Barry; John T Harty; Ann B Hill; Jeffrey C Nolz
Journal:  Sci Immunol       Date:  2017-10-13

6.  NK cells activated by Interleukin-4 in cooperation with Interleukin-15 exhibit distinctive characteristics.

Authors:  Tsuyoshi Kiniwa; Yutaka Enomoto; Natsumi Terazawa; Ai Omi; Naoko Miyata; Kenji Ishiwata; Atsushi Miyajima
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

7.  Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.

Authors:  Alain P Vicari; Alain M Schoepfer; Bertrand Meresse; Laurence Goffin; Olivier Léger; Soheila Josserand; Nicolas Guégan; Shida Yousefi; Alex Straumann; Nadine Cerf-Bensussan; Hans-Uwe Simon; Yolande Chvatchko
Journal:  MAbs       Date:  2017-06-05       Impact factor: 5.857

8.  IL-15 Enables Septic Shock by Maintaining NK Cell Integrity and Function.

Authors:  Yin Guo; Liming Luan; Naeem K Patil; Jingbin Wang; Julia K Bohannon; Whitney Rabacal; Benjamin A Fensterheim; Antonio Hernandez; Edward R Sherwood
Journal:  J Immunol       Date:  2016-12-28       Impact factor: 5.422

Review 9.  Interleukin-15 in the treatment of cancer.

Authors:  Thomas A Waldmann
Journal:  Expert Rev Clin Immunol       Date:  2014-10-31       Impact factor: 4.473

10.  Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion.

Authors:  Avishai Shemesh; Harry Pickering; Kole T Roybal; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-06-27       Impact factor: 17.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.